AKT1 and non-small cell lung carcinoma: Previous reports have demonstrated that shikonin can inhibit PI3K/Akt signaling in lung cancer A549 cells [32], afatinib-resistant NSCLC cells [33], and paclitaxel-resistance A549 cells [34].